Skye Bioscience, Inc.
SKYE
$3.29
-$0.26-7.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -42.37M | -32.65M | -26.57M | -21.24M | -42.29M |
| Total Depreciation and Amortization | 605.80K | 448.50K | 298.70K | 151.80K | 114.60K |
| Total Amortization of Deferred Charges | 111.50K | 361.80K | 599.00K | 826.50K | 817.40K |
| Total Other Non-Cash Items | 3.79M | 3.93M | 3.06M | 1.22M | 25.20M |
| Change in Net Operating Assets | 4.50M | -1.80M | -2.63M | -1.87M | -3.55M |
| Cash from Operations | -33.37M | -29.71M | -25.24M | -20.91M | -19.70M |
| Capital Expenditure | -1.57M | -1.61M | -1.60M | -1.56M | -46.40K |
| Sale of Property, Plant, and Equipment | 302.60K | 213.20K | 1.36M | 1.22M | 1.15M |
| Cash Acquisitions | -- | -- | -- | 0.00 | 1.08M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -24.75M | -12.80M | -- | -- | -- |
| Cash from Investing | -26.02M | -14.20M | -245.60K | -343.00K | 2.18M |
| Total Debt Issued | -- | -- | -- | 0.00 | 4.97M |
| Total Debt Repaid | -- | -- | -- | -22.70K | -90.70K |
| Issuance of Common Stock | 6.44M | 6.44M | 92.09M | 85.92M | 97.65M |
| Repurchase of Common Stock | -- | -2.10M | -2.10M | -2.10M | -2.10M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.42M | -6.43M | -6.43M | -265.10K | -271.10K |
| Cash from Financing | 23.80K | -2.09M | 83.56M | 83.53M | 100.17M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -59.36M | -46.00M | 58.08M | 62.28M | 82.64M |